一品紅(300723.SZ):全資子公司獲得間苯三酚注射液註冊證書
格隆匯6月4日丨一品紅(300723.SZ)公佈,公司全資子公司廣州市聯瑞製藥有限公司於近日收到國家藥品監督管理局核准簽發的關於間苯三酚注射液的《藥品註冊證書》。
根據核准的説明書,間苯三酚注射液適應症為:消化系統和膽道功能障礙引起的急性痙攣性疼痛;急性痙攣性尿道、膀胱、腎絞痛;婦科痙攣性疼痛。
間苯三酚注射液是國家醫保乙類產品。公司獲批的間苯三酚注射液是以化學藥品4類申報註冊,視同通過一致性評價。根據米內網數據,2024年間苯三酚注射液在中國城市和縣級公立醫院的銷售規模約為8.3751億元人民幣。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.